【Description】
These include nintedanib (Ofev®) and pirfenidone (Esbriet®). These medications are called anti-fibrotic agents, meaning that they have shown in clinical trials to slow down the rate of fibrosis or scarring in the lungs. These drugs are approved for patients with mild, moderate and severe IPF.
The global market for Idiopathic Pulmonary Fibrosis (IPF) Drug was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Idiopathic Pulmonary Fibrosis (IPF) Drug was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Idiopathic Pulmonary Fibrosis (IPF) Drug was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Idiopathic Pulmonary Fibrosis (IPF) Drug was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Idiopathic Pulmonary Fibrosis (IPF) Drug include American Lung Association, Roche, Genentech and Fierce Pharma, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Idiopathic Pulmonary Fibrosis (IPF) Drug, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Idiopathic Pulmonary Fibrosis (IPF) Drug by region & country, by Type, and by Application.
The Idiopathic Pulmonary Fibrosis (IPF) Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Idiopathic Pulmonary Fibrosis (IPF) Drug.
Market Segmentation
By Company
American Lung Association
Roche
Genentech
Fierce Pharma
Segment by Type:
Nintedanib
Pirfenidone
Segment by Application
Hospital
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Idiopathic Pulmonary Fibrosis (IPF) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Idiopathic Pulmonary Fibrosis (IPF) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Idiopathic Pulmonary Fibrosis (IPF) Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
【Table of Contents】
1 Market Overview
1.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Product Introduction
1.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size Forecast
1.2.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value (2019-2030)
1.2.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume (2019-2030)
1.2.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Price (2019-2030)
1.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Trends & Drivers
1.3.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Industry Trends
1.3.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Drivers & Opportunity
1.3.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Challenges
1.3.4 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Players Revenue Ranking (2023)
2.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Company (2019-2024)
2.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Players Sales Volume Ranking (2023)
2.4 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Company Players (2019-2024)
2.5 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Company (2019-2024)
2.6 Key Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Idiopathic Pulmonary Fibrosis (IPF) Drug
2.9 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Competitive Analysis
2.9.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis (IPF) Drug as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Nintedanib
3.1.2 Pirfenidone
3.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type
3.2.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, by Type (2019-2030)
3.2.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, by Type (%) (2019-2030)
3.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Type
3.3.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume, by Type (2019-2030)
3.3.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume, by Type (%) (2019-2030)
3.4 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinics
4.1.3 Others
4.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application
4.2.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, by Application (2019-2030)
4.2.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, by Application (%) (2019-2030)
4.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Application
4.3.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume, by Application (2019-2030)
4.3.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume, by Application (%) (2019-2030)
4.4 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Region
5.1.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Region (2019-2024)
5.1.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Region (2025-2030)
5.1.4 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Region (%), (2019-2030)
5.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Region
5.2.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Region (2019-2024)
5.2.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Region (2025-2030)
5.2.4 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Region (%), (2019-2030)
5.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, 2019-2030
5.4.2 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, 2019-2030
5.5.2 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, 2019-2030
5.6.2 Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, 2019-2030
5.7.2 South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, 2019-2030
5.8.2 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value
6.2.1 Key Countries/Regions Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, 2019-2030
6.2.2 Key Countries/Regions Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, 2019-2030
6.3.2 United States Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, 2019-2030
6.4.2 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, 2019-2030
6.5.2 China Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (%), 2023 VS 2030
6.5.3 China Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, 2019-2030
6.6.2 Japan Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, 2019-2030
6.7.2 South Korea Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, 2019-2030
6.8.2 Southeast Asia Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, 2019-2030
6.9.2 India Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (%), 2023 VS 2030
6.9.3 India Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 American Lung Association
7.1.1 American Lung Association Company Information
7.1.2 American Lung Association Introduction and Business Overview
7.1.3 American Lung Association Idiopathic Pulmonary Fibrosis (IPF) Drug Sales, Revenue and Gross Margin (2019-2024)
7.1.4 American Lung Association Idiopathic Pulmonary Fibrosis (IPF) Drug Product Offerings
7.1.5 American Lung Association Recent Development
7.2 Roche
7.2.1 Roche Company Information
7.2.2 Roche Introduction and Business Overview
7.2.3 Roche Idiopathic Pulmonary Fibrosis (IPF) Drug Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Roche Idiopathic Pulmonary Fibrosis (IPF) Drug Product Offerings
7.2.5 Roche Recent Development
7.3 Genentech
7.3.1 Genentech Company Information
7.3.2 Genentech Introduction and Business Overview
7.3.3 Genentech Idiopathic Pulmonary Fibrosis (IPF) Drug Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Genentech Idiopathic Pulmonary Fibrosis (IPF) Drug Product Offerings
7.3.5 Genentech Recent Development
7.4 Fierce Pharma
7.4.1 Fierce Pharma Company Information
7.4.2 Fierce Pharma Introduction and Business Overview
7.4.3 Fierce Pharma Idiopathic Pulmonary Fibrosis (IPF) Drug Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Fierce Pharma Idiopathic Pulmonary Fibrosis (IPF) Drug Product Offerings
7.4.5 Fierce Pharma Recent Development
8 Industry Chain Analysis
8.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Industrial Chain
8.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Model
8.5.2 Sales Channel
8.5.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
【Table of Figures】
List of Tables
Table 1. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Trends
Table 2. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Drivers & Opportunity
Table 3. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Challenges
Table 4. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Restraints
Table 5. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Company (2019-2024)
Table 7. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Idiopathic Pulmonary Fibrosis (IPF) Drug Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Idiopathic Pulmonary Fibrosis (IPF) Drug
Table 13. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis (IPF) Drug as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Region (2019-2024) & (%)
Table 44. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Region (2025-2030) & (%)
Table 45. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Region (2019-2024) & (%)
Table 49. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Region (2025-2030) & (%)
Table 50. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume, (2025-2030) & (K Units)
Table 57. American Lung Association Company Information
Table 58. American Lung Association Introduction and Business Overview
Table 59. American Lung Association Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. American Lung Association Idiopathic Pulmonary Fibrosis (IPF) Drug Product Offerings
Table 61. American Lung Association Recent Development
Table 62. Roche Company Information
Table 63. Roche Introduction and Business Overview
Table 64. Roche Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Roche Idiopathic Pulmonary Fibrosis (IPF) Drug Product Offerings
Table 66. Roche Recent Development
Table 67. Genentech Company Information
Table 68. Genentech Introduction and Business Overview
Table 69. Genentech Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Genentech Idiopathic Pulmonary Fibrosis (IPF) Drug Product Offerings
Table 71. Genentech Recent Development
Table 72. Fierce Pharma Company Information
Table 73. Fierce Pharma Introduction and Business Overview
Table 74. Fierce Pharma Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Fierce Pharma Idiopathic Pulmonary Fibrosis (IPF) Drug Product Offerings
Table 76. Fierce Pharma Recent Development
Table 77. Key Raw Materials Lists
Table 78. Raw Materials Key Suppliers Lists
Table 79. Idiopathic Pulmonary Fibrosis (IPF) Drug Downstream Customers
Table 80. Idiopathic Pulmonary Fibrosis (IPF) Drug Distributors List
Table 81. Research Programs/Design for This Report
Table 82. Key Data Information from Secondary Sources
Table 83. Key Data Information from Primary Sources
List of Figures
Figure 1. Idiopathic Pulmonary Fibrosis (IPF) Drug Product Picture
Figure 2. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume (2019-2030) & (K Units)
Figure 5. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Price (2019-2030) & (US$/Unit)
Figure 6. Idiopathic Pulmonary Fibrosis (IPF) Drug Report Years Considered
Figure 7. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue in 2023
Figure 10. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Nintedanib Picture
Figure 12. Pirfenidone Picture
Figure 13. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value Market Share by Type, 2023 & 2030
Figure 15. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 16. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume Market Share by Type, 2023 & 2030
Figure 17. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price by Type (2019-2030) & (US$/Unit)
Figure 18. Product Picture of Hospital
Figure 19. Product Picture of Clinics
Figure 20. Product Picture of Others
Figure 21. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value Market Share by Application, 2023 & 2030
Figure 23. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 24. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume Market Share by Application, 2023 & 2030
Figure 25. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price by Application (2019-2030) & (US$/Unit)
Figure 26. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value (2019-2030) & (US$ Million)
Figure 27. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Country (%), 2023 VS 2030
Figure 28. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value (2019-2030) & (US$ Million)
Figure 29. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Country (%), 2023 VS 2030
Figure 30. Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Country (%), 2023 VS 2030
Figure 32. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value (2019-2030) & (US$ Million)
Figure 33. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Country (%), 2023 VS 2030
Figure 34. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value (2019-2030) & (US$ Million)
Figure 35. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Country (%), 2023 VS 2030
Figure 36. Key Countries/Regions Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value (%), (2019-2030)
Figure 37. Key Countries/Regions Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Volume (%), (2019-2030)
Figure 38. United States Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, (2019-2030) & (US$ Million)
Figure 39. United States Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (%), 2023 VS 2030
Figure 40. United States Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application (%), 2023 VS 2030
Figure 41. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, (2019-2030) & (US$ Million)
Figure 42. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (%), 2023 VS 2030
Figure 43. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application (%), 2023 VS 2030
Figure 44. China Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, (2019-2030) & (US$ Million)
Figure 45. China Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (%), 2023 VS 2030
Figure 46. China Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application (%), 2023 VS 2030
Figure 47. Japan Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, (2019-2030) & (US$ Million)
Figure 48. Japan Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (%), 2023 VS 2030
Figure 49. Japan Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application (%), 2023 VS 2030
Figure 50. South Korea Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, (2019-2030) & (US$ Million)
Figure 51. South Korea Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (%), 2023 VS 2030
Figure 52. South Korea Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application (%), 2023 VS 2030
Figure 53. Southeast Asia Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, (2019-2030) & (US$ Million)
Figure 54. Southeast Asia Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (%), 2023 VS 2030
Figure 55. Southeast Asia Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application (%), 2023 VS 2030
Figure 56. India Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value, (2019-2030) & (US$ Million)
Figure 57. India Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Type (%), 2023 VS 2030
Figure 58. India Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Value by Application (%), 2023 VS 2030
Figure 59. Idiopathic Pulmonary Fibrosis (IPF) Drug Industrial Chain
Figure 60. Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturing Cost Structure
Figure 61. Channels of Distribution (Direct Sales, and Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed